Table 2.
Number of patients, events, crude incidences, age- and sex-adjusted hazard ratios (HRas), and fully adjusted hazard ratios (HRbs) for overall invasive cancer, excluding skin cancer, in Swedish patients with RA treated or untreated with b/tsDMARDs, with b/tsDMARD-naïve RA and the general population as references
| Cohort | Patient episodes | Events | Person-years of follow-up | Crude incidence per 1000 | HRa (95% Cl) B/tsDMARD-naïve | HRb (95% Cl) | HRa (95% CI) general population |
|---|---|---|---|---|---|---|---|
| TNFi | 33 609 | 2395 | 224 661.2 | 10.7 | 1.0 (0.9, 1.0) | 1.0 (0.9, 1.0) | 1.1 (1.0, 1.2)a |
| RTX | 4367 | 294 | 22 846.9 | 12.9 | 1.0 (0.9, 1.1) | 1.0 (0.9, 1.1) | 1.1 (1.0, 1.3)b |
| ABT | 3558 | 180 | 13 604.6 | 13.6 | 1.2 (1.0, 1.4)c | 1.2 (1.0, 1.3)d | 1.3 (1.1, 1.6) |
| TCZ | 2895 | 119 | 11 572.3 | 11.6 | 1.0 (0.8, 1.2) | 1.0 (0.8, 1.2) | 1.1 (0.9, 1.3) |
| B/tsDMARD-naïve | 58 233 | 5642 | 38 5173.5 | 14.6 | 1.0 (reference) | 1.0 (reference) | 1.2 (1.1, 1.2)e |
| General population | 215 592 | 13 205 | 1 335 994.4 | 9.9 | 0.9 (0.8, 0.9) | NA | 1.0 (reference) |
HR = 1.10 (1.04, 1.16).
HR = 1.14 (1.00, 1.29).
HR = 1.16 (1.00, 1.36).
HR = 1.15 (0.98, 1.34).
HR = 1.15 (1.11, 1.19).
TNFi: TNF inhibitor; RTX: rituximab; ABT: abatacept; TCZ: tocilizumab; HR: hazard ratio; HRa: hazard ratio adjusted for attained age, year of start of follow-up, and sex; HRb, as for HRa, plus adjustment for selected comorbidities, NSAID use, steroid use, educational level, sick leave and disability as defined at baseline, i.e. fully adjusted; NA: not applicable; ref.: reference.